DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Smoking Relapse-Prevention Intervention for Cancer Patients

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Usual Care
Behavioral: Smoking Relapse Prevention for Cancer Patients (SRP-CaP)

First Posted Date: 2012-06-28

Last Posted Date: 2021-08-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 441

Registration Number: NCT01630161

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Phase 1

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Valrubicin

First Posted Date: 2012-05-25

Last Posted Date: 2016-04-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 4

Registration Number: NCT01606345

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Stress Management Training for Latinas Receiving Chemotherapy

Not Applicable

Completed

Conditions: Cancer
Stress

Interventions: Behavioral: Usual Care Only
Behavioral: Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)

First Posted Date: 2012-05-16

Last Posted Date: 2022-01-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 140

Registration Number: NCT01599520

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

Phase 2

Completed

Conditions: Liver Cancer
Pancreatic Cancer

Interventions: Drug: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)
Device: TheraSpheres

First Posted Date: 2012-04-20

Last Posted Date: 2017-03-03

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 9

Registration Number: NCT01581307

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Androgen Ablation
Drug: Cabazitaxel
Drug: Salvage Therapy
Drug: Neoadjuvant Treatment - Hormonal Therapy
Drug: Neoadjuvant Treatment - Cabazitaxel

First Posted Date: 2012-02-10

Last Posted Date: 2014-11-05

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 2

Registration Number: NCT01531205

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Metformin in Children With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Primary Brain Tumors
Solid Tumors

Interventions: Drug: Vincristine
Drug: Irinotecan
Drug: Temozolomide
Drug: Metformin

First Posted Date: 2012-02-07

Last Posted Date: 2023-01-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 26

Registration Number: NCT01528046

Locations: 🇺🇸
Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 11 locations

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: High Dose Methylprednisolone (HDMP)
Drug: Ofatumumab
Drug: Lenalidomide

First Posted Date: 2011-12-22

Last Posted Date: 2021-04-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 29

Registration Number: NCT01497496

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: High Dose Methylprednisolone (HDMP)
Drug: Ofatumumab
Drug: Lenalidomide

First Posted Date: 2011-12-22

Last Posted Date: 2025-05-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 45

Registration Number: NCT01496976

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: Sylatron
Drug: Yervoy

First Posted Date: 2011-12-21

Last Posted Date: 2017-04-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 31

Registration Number: NCT01496807

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Preparedness Study - HPV Vaccine

Not Applicable

Completed

Conditions: Sexual Transmission of Infection

Interventions: Other: Placebo
Biological: Gardasil Vaccine

First Posted Date: 2011-12-09

Last Posted Date: 2015-02-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 406

Registration Number: NCT01489527

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇿🇦
Stellenbosch University, Parow, South Africa

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy